Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$124.84 USD
+0.22 (0.18%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $124.87 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 21 - 40 ( 678 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: EMBARK-ing on a New Year with Sights Set on ELEVIDYS Label Expansion
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficacy Supplement to ELEVIDYS'' BLA Accepted; Review Goal Date of June 21
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 21224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Topline Part B MOMENTUM Data for SRP-5051; Near-Term Focus Remains on ELEVIDYS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 12224
Provider: Stock Traders Daily
Analyst: Research Department